362 related articles for article (PubMed ID: 26412302)
1. Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension.
Uschner FE; Ranabhat G; Choi SS; Granzow M; Klein S; Schierwagen R; Raskopf E; Gautsch S; van der Ven PF; Fürst DO; Strassburg CP; Sauerbruch T; Diehl AM; Trebicka J
Sci Rep; 2015 Sep; 5():14573. PubMed ID: 26412302
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase.
Trebicka J; Hennenberg M; Laleman W; Shelest N; Biecker E; Schepke M; Nevens F; Sauerbruch T; Heller J
Hepatology; 2007 Jul; 46(1):242-53. PubMed ID: 17596891
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats.
Schwabl P; Payer BA; Grahovac J; Klein S; Horvatits T; Mitterhauser M; Stift J; Boucher Y; Trebicka J; Trauner M; Angermayr B; Fuhrmann V; Reiberger T; Peck-Radosavljevic M
J Hepatol; 2014 Jun; 60(6):1135-42. PubMed ID: 24530596
[TBL] [Abstract][Full Text] [Related]
4. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
Klein S; Rick J; Lehmann J; Schierwagen R; Schierwagen IG; Verbeke L; Hittatiya K; Uschner FE; Manekeller S; Strassburg CP; Wagner KU; Sayeski PP; Wolf D; Laleman W; Sauerbruch T; Trebicka J
Gut; 2017 Jan; 66(1):145-155. PubMed ID: 26385087
[TBL] [Abstract][Full Text] [Related]
5. Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis.
Zhang CG; Zhang B; Deng WS; Duan M; Chen W; Wu ZY
World J Gastroenterol; 2016 May; 22(18):4484-500. PubMed ID: 27182159
[TBL] [Abstract][Full Text] [Related]
6. AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model.
Hu L; Su L; Dong Z; Wu Y; Lv Y; George J; Wang J
J Mol Med (Berl); 2019 Mar; 97(3):423-434. PubMed ID: 30721324
[TBL] [Abstract][Full Text] [Related]
7. Increased angiogenesis and permeability in the mesenteric microvasculature of rats with cirrhosis and portal hypertension: an in vivo study.
Geerts AM; De Vriese AS; Vanheule E; Van Vlierberghe H; Mortier S; Cheung KJ; Demetter P; Lameire N; De Vos M; Colle I
Liver Int; 2006 Sep; 26(7):889-98. PubMed ID: 16911473
[TBL] [Abstract][Full Text] [Related]
8. Acute effects of endothelin receptor antagonists on hepatic hemodynamics of cirrhotic and noncirrhotic rats.
Cavasin MA; Semus H; Pitts K; Peng Y; Sandoval J; Chapo J; Plato CF
Can J Physiol Pharmacol; 2010 Jun; 88(6):636-43. PubMed ID: 20628429
[TBL] [Abstract][Full Text] [Related]
9. A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats.
Rodríguez S; Raurell I; Torres-Arauz M; García-Lezana T; Genescà J; Martell M
Sci Rep; 2017 Jan; 7():40461. PubMed ID: 28084470
[TBL] [Abstract][Full Text] [Related]
10. Sequential Functions of CPEB1 and CPEB4 Regulate Pathologic Expression of Vascular Endothelial Growth Factor and Angiogenesis in Chronic Liver Disease.
Calderone V; Gallego J; Fernandez-Miranda G; Garcia-Pras E; Maillo C; Berzigotti A; Mejias M; Bava FA; Angulo-Urarte A; Graupera M; Navarro P; Bosch J; Fernandez M; Mendez R
Gastroenterology; 2016 Apr; 150(4):982-97.e30. PubMed ID: 26627607
[TBL] [Abstract][Full Text] [Related]
11. Insulin reverses major portal hypertension-related derangements in rats with liver cirrhosis and diabetes.
Hsin IF; Huang HC; Chang CC; Hsu SJ; Lee FY; Huo TI; Chuang CL; Hou MC; Lee SD
Clin Sci (Lond); 2018 Nov; 132(22):2391-2405. PubMed ID: 30348829
[TBL] [Abstract][Full Text] [Related]
12. Disruption of negative feedback loop between vasohibin-1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats.
Coch L; Mejias M; Berzigotti A; Garcia-Pras E; Gallego J; Bosch J; Mendez R; Fernandez M
Hepatology; 2014 Aug; 60(2):633-47. PubMed ID: 24390792
[TBL] [Abstract][Full Text] [Related]
13. Sodium ferulate lowers portal pressure in rats with secondary biliary cirrhosis through the RhoA/Rho-kinase signaling pathway: a preliminary study.
Wei L; Yang J; Wang M; Xu SN; Liang HM; Zhou Q
Int J Mol Med; 2014 Nov; 34(5):1257-67. PubMed ID: 25174394
[TBL] [Abstract][Full Text] [Related]
14. Procyanidin B2 inhibits the activation of hepatic stellate cells and angiogenesis via the Hedgehog pathway during liver fibrosis.
Feng J; Wang C; Liu T; Li J; Wu L; Yu Q; Li S; Zhou Y; Zhang J; Chen J; Ji J; Chen K; Mao Y; Wang F; Dai W; Fan X; Wu J; Guo C
J Cell Mol Med; 2019 Sep; 23(9):6479-6493. PubMed ID: 31328391
[TBL] [Abstract][Full Text] [Related]
15. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.
Schwabl P; Hambruch E; Seeland BA; Hayden H; Wagner M; Garnys L; Strobel B; Schubert TL; Riedl F; Mitteregger D; Burnet M; Starlinger P; Oberhuber G; Deuschle U; Rohr-Udilova N; Podesser BK; Peck-Radosavljevic M; Reiberger T; Kremoser C; Trauner M
J Hepatol; 2017 Apr; 66(4):724-733. PubMed ID: 27993716
[TBL] [Abstract][Full Text] [Related]
16. Glycyrrhizin Attenuates Portal Hypertension and Collateral Shunting via Inhibition of Extrahepatic Angiogenesis in Cirrhotic Rats.
Pun CK; Huang HC; Chang CC; Chuang CL; Yen CH; Hsu SJ; Lee FY; Hou MC; Huang YH
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299285
[TBL] [Abstract][Full Text] [Related]
17. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats.
Verbeke L; Farre R; Trebicka J; Komuta M; Roskams T; Klein S; Elst IV; Windmolders P; Vanuytsel T; Nevens F; Laleman W
Hepatology; 2014 Jun; 59(6):2286-98. PubMed ID: 24259407
[TBL] [Abstract][Full Text] [Related]
18. Sodium Ferulate Reduces Portal Pressure Through Inhibition of RhoA/Rho-Kinase and Activation of Endothelial Nitric Oxide Synthase in Cirrhotic Rats.
Liu J; Peng L; Yang J; Wang M; Xu S; Liu J; Han P; He J; Tian D; Zhou Q
Dig Dis Sci; 2015 Jul; 60(7):2019-29. PubMed ID: 25724163
[TBL] [Abstract][Full Text] [Related]
19. Influence of miR-26b on hepatic cirrhosis and portal pressure in rats with cirrhotic portal hypertension by targeting hENT1 depending on RhoA/ROCK-1 pathway.
Chen Y; Tian Y
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1668-1673. PubMed ID: 30840291
[TBL] [Abstract][Full Text] [Related]
20. Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertension.
Schwabl P; Seeland BA; Riedl F; Schubert TL; Königshofer P; Brusilovskaya K; Petrenko O; Hofer B; Schiefer AI; Trauner M; Peck-Radosavljevic M; Reiberger T
Adv Med Sci; 2022 Mar; 67(1):154-162. PubMed ID: 35272246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
